OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

Charity Number: 1176307

The ecancer Global Foundation

FINANCIAL STATEMENTS

For the Year Ended 31 December 2024

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

C O N T E N T S
Page
LEGAL AND ADMINISTRATIVE DETAILS 1
TRUSTEES’ REPORT 2 - 5
AUDITOR’S REPORT 6 - 8
STATEMENT OF FINANCIAL ACTIVITIES 9
BALANCE SHEET 10
STATEMENT OF CASH FLOWS 11
NOTES TO THE FINANCIAL STATEMENTS
12-17

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

Principal address

Independent Examiners

The ecancer Global Foundation 13 King Square Avenue Bristol BS2 8HU

Hazlewoods LLP Windsor House Bayshill Road Cheltenham GL50 3AT

Trustees:

The trustees who served during the year were:

Emily Sarah Kobbe Penelope Jane Crocker Professor Richard Sullivan James Isola Cristian Herra Groesbeck Parham

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Message from the chair

2024 has been a year of meaningful progress and renewed purpose for ecancer. As the world of oncology continues to evolve at pace in a more uncertain and financially challenging global environment, our commitment to equitable access to high-quality education has never been more vital. This year, the ecancer team has worked tirelessly to expand our global reach, strengthen partnerships, and ensure that healthcare professionals everywhere can access the knowledge they need to improve patient care.

ecancer.org continues to thrive, reaching more healthcare professionals than ever before with a 17% increase in visitors from 2023; a record number and a remarkable achievement! The growing global community of learners engaging with ecancer.org reflects the increasing need for accessible, high-quality oncology education, particularly in low- and middle-income countries where resources remain limited. The rise in new registrations this year is testament to the trust placed in ecancer as a valued, independent educational partner that reflects the priorities of the global community.

Our open access journal, ecancermedicalscience , has gone from strength to strength, publishing a steady flow of high-quality research in both English and Spanish. In 2024, we saw a 35% increase in submissions and a 22% increase in published articles, both reaching record levels. This reflects the growing recognition of the journal as a trusted and inclusive platform for oncology research. The journal continues to uphold our unique “pay what you can afford” model, removing financial barriers to publication and ensuring that authors from all regions can contribute to global cancer knowledge. The readership of our articles continues to expand, demonstrating the reach and relevance of our editorial work.

Video education remains at the heart of our mission to share the latest developments in cancer care and policy. Our production teams have travelled to major oncology conferences around the world, capturing expert interviews and insights to ensure that clinicians everywhere can access the most up-to-date information. Engagement with our videos continues to grow, underscoring their vital role in bridging global knowledge gaps.

The e-learning platform has also expanded its resources, with new courses developed in response to emerging educational needs and thousands of modules completed by healthcare professionals seeking to update their knowledge and skills. Complementing this, our news service continues to provide timely, trusted coverage of developments from across the cancer community, helping readers stay informed in an ever-evolving field.

Our global engagement has deepened through both our events programme and our participation in international research. In 2024, we delivered impactful educational meetings that brought together leading experts and practitioners to share experiences and drive improvements in cancer care. We were also proud to continue our involvement in collaborative research projects such as iBeChange, which addresses behavioural and lifestyle risk factors to support cancer prevention.

As we look ahead to 2025, our focus remains clear: to expand our educational reach, deepen collaborations, and continue providing the free, high-quality resources that empower healthcare professionals everywhere to deliver better cancer care.

On behalf of the Trustees, I would like to thank our truly exceptional team, led by CEO Danny Burke, all our partners and supporters for their dedication and belief in ecancer’s mission. Together, we are making a meaningful difference in cancer education and global health.

Professor Richard Sullivan

Chair of Trustees

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2024

Stats: Key 2024 highlights ecancer.org - 764,000 learners - 3,426 new registrations

Video

Journal (ecancermedicalscience)

e-learning

News

Research projects

We are partners in the following research project:

 iBeChange - Addressing psychological and lifestyle risk factors to promote primary cancer prevention

Events

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2024

Report of the Trustees

The Trustees hereby present the statutory report, with the accounts of The ecancer Global Foundation, for the year ending 31 December 2024.

The results for the year are presented in the form of a Statement of Financial Activities, which incorporates the traditional income and expenditure account, in order to comply with the Statement of Recommended Practice for Charities, and in accordance with the Charities Act 2011.

The Trust

The accounts accompanying this report are the accounts of the charitable trust. It is registered with the Charities Commission, Charity Registration number 1176307.

Charitable objectives

Our vision

A world in which every cancer patient receives the best possible care and treatment.

Our mission and future plans

e cancer's mission is to raise the standards of care for cancer patients across the world through education. Over the next 12 months, ecancer will focus on expanding the number of learners engaging with our resources as well as developing all aspects of our work to meet the needs of the global oncology community.

Public benefit statement:

The ecancer Global Foundation’s charitable purpose is carried out for the public benefit in accordance with our vision and mission. The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Charity Commission’s general guidance on Charities and Public Benefit.

Educational activities for healthcare professionals

The majority of the oncology professionals who engage with our educational resources do so through our open access and free website, ecancer.org. The site provides a vast knowledge bank covering every cancer type which are developed in partnership with leading global experts to meet regional educational needs. ecancer.org has been publishing free education for the oncology community since 2007 and, as such, has an established audience from around the world.

As well as ecancer.org, our ethos is to provide educational resources to the global oncology community wherever there is a need to as wide an online audience as possible. Our resources are therefore also disseminated through platforms such as YouTube, PubMed, Twitter, Facebook, LinkedIn, Scopus, Web of Science, Embase, EBSCO and Google Scholar as well as other educational partners such as the Union for International Cancer Control (UICC), the International Cancer Control Partnership and the International Society for Geriatric Oncology (SIOG).

A section of ecancer.org is dedicated to healthcare professionals in Latin America with content in predominantly in Spanish but also in Portuguese. We have native Spanish speakers who manage and maintain this section with support from our other team members.

We also publish ecancerpatient.org which is a patient-focused website that provides the latest cancer information direct from experts in an easy-to-understand format that was developed in partnership with patient groups. The goal is to empower patients to be more involved in the decision-making process when it comes to their care.

Our series of educational events in under-served areas of the world is now well established in Latin America and has launched in India with fantastic educational partners allowing us to deliver high quality education in areas of the world that need it most.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation TRUSTEES’ REPORT CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2024

Trustee Recruitment and training programme

The existing Trustees and CEO review any gaps in the group of Trustees on an ongoing basis, and if there is a shortage, will review suitable individuals who fit the requirements profile. Any individual is then approached and recruited, and follows the charity’s training and induction process.

Pay and remuneration is reviewed on an annual basis as part of the budgeting process, and is agreed at Trustee level.

Decision making

The charity is managed by the CEO, with support from the Senior Management Team. Key decisions likely to significantly impact the organisation are agreed by the CEO and Trustees, who review and evaluate in detail.

Risk Assessment

In accordance with the SORP requirements, the Trustees carry out wide-ranging reviews of the risks faced by the charity. These reviews look particularly at Health and Safety issues, management and financial accountability and internal security. The Trustees are satisfied that all appropriate and feasible measures have been put in place to reduce the risks to which the charity is exposed. As a consequence of this, the Trustees have greater awareness of the kinds of risks which could affect the charity and have implemented strategies to reduce such risks.

Reserves policy and financial position

As a young charity, we are currently in the process of building reserves to achieve the aims of the organisation which is to maintain free unrestricted reserves:

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The Trustees of the Charity are required to prepare for each financial year accounts which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that period. In preparing those financial statements, the trustees are required to:

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed dated 15 December 2017. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

21/10/2025

Approved by the Trustees on …………..…… and signed as authorised

…………………………….. Prof. Richard Sullivan

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

We have audited the financial statements of The ecancer Global Foundation for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Opinion on financial statements

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

Other information

The other information comprises the information included in the annual report, other than the financial statement and our auditor’s report thereon. The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities Act 2011 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation AUDITOR’S REPORT TO THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

Extent to which the audit was considered capable of detecting irregularities, including fraud

Owing to the inherent limitations of an audit, there is an unavoidable risk that material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISA’s (UK).

In identifying and assessing risks of material mis-statement in respect of fraud, including irregularities and noncompliance with laws and regulations, our procedures included the following:

• We obtained an understanding of the legal and regulatory frameworks applicable to the company financial statements or that had a fundamental effect on the company’s operations. We determined that the most significant laws and regulations included UK GAAP, UK Companies Act 2006 and taxation laws.

• We understood how the company is complying with those legal and regulatory frameworks by making inquiries of management, those responsible for legal and compliance procedures.

• We assessed the susceptibility of the company’s financial statements to material misstatement, including how fraud might occur. Audit procedures performed by the engagement team included:

• Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;

• Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process. Detailed analysis of journals posted through the accounting system during the year to 31 December 2024 has been undertaken;

• Understanding the controls in place to prevent and detect fraud. Reliance was not placed on controls for the entirety of the audit, instead taking a substantive testing approach, however controls were in place to prevent fraud, and they appeared to be working effectively;

• Challenging assumptions and judgements made by management in its significant accounting estimates.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with the Charities Act 2011. Our audit work has been undertaken so that we might state to the trustees those matters we are required to state to them in an auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

----- Start of picture text -----
………………………
----- End of picture text -----

……………………… Martin Howard (Senior Statutory Auditor) For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House Bayshill Road Cheltenham GL50 3AT

21/10/2025 Date: …………………

Hazlewoods LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2024

INCOMING
RESOURCES
Unrestricted funds
Notes
Donations and
legacies
Grant amortisation
Charitable
Activities
E-learning
Events
Journal
Educational video
Other Activities to
Generate
Funds
Advertising income
Total Incoming
Resources
Resources
Expended
Raising funds
Charitable
Expenditure
E-learning
Events
Journal
Research projects
Educational videos
Website
Advertising
Total Resources
Expended
2
Net movements in
funds
Transfer between
funds
Total funds
brought forward
Balance carried
forward at 31
December 2024		 Unrestricted
funds
2024
£
30,529
661
8,119
-
-
261,606
142,112
443,027
97,203
18,443
61,876
-
-
145,630
-
223
323,375
323,375
119,652
(265,002)
(438,437)
(583,787)		 Restricted
funds 2024
£
912
-
24,068
7,234
20,273
477,114
-
529,601
-
73,268
67,196
106,066
354
248,747
92,645
-
588,276
588,276
(58,675)
265,002
318,143
524,470		 Total funds
2024
£
31,441
661
32,187
7,234
20,273
738,720
142,112
972,628
97,203
91,711
129,072
106,066
354
394,377
92,645
223
911,651
911,651
60,977
-
(120,294)
(59,317)		 Total
funds
2023
£
1,022
661
26,000
158,423
11,649
756,543
76,668
1,030,966
91,386
97,013
397,876
117,890
33,527
512,329
94,808
577
1,254,020
1,345,406
(314,440)
-
194,146
(120,294)

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation BALANCE SHEET AT 31 DECEMBER 2024

Note
Fixed assets
3,7
Current Assets
Debtors and prepayments
4,7
Cash at bank and in hand
Less Creditors: Amounts
falling due within one year
5,7
Net Current (Liabilities) / Assets
Net (Liabilities) / Assets
Represented by:
Restricted funds:
6
Unrestricted funds
6		 2024
26,182
59,367
173,474
232,841
(318,340)
(85,499)
(59,317)
524,470
(583,787)
(59,317)		 2023
£
35,225
166,217
136,053
302,270
(457,789)
(155,519)
(120,294)
318,143
(438,437)
(120,294)

21/10/2025

Approved by the trustees on ………………. and signed on their behalf by:

………………….. Prof R Sullivan

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024

2024
2023
£
£
Cash flows from operating activities
Surplus / (deficit) for the year 60,977
(314,440)
Adjustments to cash flows from non-cash items
Depreciation and amortisation 10,364
10,112
71,341
(304,328)
Working capital adjustments
Increase in debtors 106,850
171,597
Decrease in creditors (139,449)
(21,848)
Cash generated from / (in) operations (32,599)
149,749
Net cash flow from operatingactivities 38,742
(154,579)
Cash flows from investing activities
Acquisitions of tangible assets (1,321)
(4,185)
Net cash flows from investingactivities (1,321)
(4,185)
Net (decrease)/increase in cash and cash equivalents 37,421
(158,764)
Cash and cash equivalents at 1 January 136,053
294,817
Cash and cash equivalents at 31 December 173,474
136,053

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting Policies

Basis of Preparation

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain fixed assets, adopting the following principal accounting policies all of which are in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Charities Act 2011.

General information

The financial statements are presented in Pounds Sterling. The charity is a public benefit charitable incorporated organisation, incorporated in England and Wales.

The address of its registered office is: 13 King Square Avenue Bristol BS2 8HU

Judgements and estimation uncertainty

The trustees consider that there are no key areas of judgement or estimation uncertainty to be disclosed in these financial statements.

Tangible fixed assets and depreciation

Tangible fixed assets are stated in the accounts at cost or revalued amount less depreciation. Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life.

Depreciation is provided to write off the cost/value of assets over their useful lives as follows:

Office equipment 5 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade receivables

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All debtors are repayable within one year and are hence included at the undiscounted amount of the cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the Charity will not be able to collect all amounts due according to the original terms of the receivables.

Trade payables

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the Charity does not have an unconditional right, at the end of the reporting year, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

Legacies, Donations and Grants Receivable

All income is recognised when receivable and when capable of financial measurement. Receipts of property investments or other gifts in kind are included at market value.

Going concern

There are no significant factors affecting the charity’s ability to continue as a going concern.

Expenditure on Charitable activities

Expenditure on Charitable activities is included in the Statement of Financial Activities on an accruals basis. Where expenditure is directly attributable to more than one activity, it is apportioned across cost categories on the basis of the proportion of income receivable relating to each activity.

Funds

Funds held by the charity are either:

Pensions

The company operates a defined contribution scheme for certain employees. The contributions are charged to revenue in the year in which they are incurred.

2. Analysis of Total Resources Expended

Charitable Expenditure
E-learning
Events
Journal
Research projects
Educational videos
Raising funds
Website and advertisements		 Direct
Activities
£
-
-
94,114
354
-
97,203
92,867
284,538		 Grant
funding
£
86,789
108,006
-
-
336,874
-
-
531,669		 Support
costs
(see 2a
below) £
4,921
21,066
11,952
-
57,505
-
-
95,444		 2024
Total
£
91,710
129,072
106,066
354
394,379
97,203
92,867
**911,651 **		 2023
Total
£
97,013
397,876
120,890
33,527
509,329
91,386
95,385
1,345,406

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The ecancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

Support costs are allocated on the basis of full-time equivalents.

Staff costs:
Wages and salaries
Social security costs
Pension costs
The average number of full time employees
In the period was		 2024
£
434,731
36,892
26,018
497,641
Number
14		 2023
£
528,190
50,624
37,686
616,500
Number
18

No employee earned £60,000 or more, and no Trustees were remunerated through the charity.

During the year, the charity made redundancy payments of £nil (2023 - £5,674).

2a. Analysis of Support Costs

E-learning
Events
Journal
Educational videos		 2024
£
4,921
21,066
11,952
57,505
95,444		 2023
£
7,262
31,089
17,638
84,865
140,854

Support costs are all allocated to charitable expenditure, other than £nil (2023 - £nil) incurred in relation to raising funds within the year.

Audit fees accrued during the year was £9,600 (2023 - £9,300). No other services were provided by the auditors.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

3. Fixed assets

Cost
At 1 January 2024
Additions
December 31, 2024
Depreciation
At 1 January 2024
Charge for the year
December 31, 2024
Net book value
December 31, 2024
December 31, 2023
4.
Debtors
Trade debtors
Prepayments and accrued income
2024
£
57,582
1,785
59,367		 Office
equipment
£
53,198
1,321
54,519
17,973
10,364
28,337
26,182
35,225
2023
£
160,892
5,325
166,217

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

5. Creditors: Amounts falling due within one year

Trade creditors
Taxation and social security
Accruals and deferred income
Other creditors
Capital grants		 2024
£
3,216
11,434
296,420
-
7,270
318,340		 2023
£
55,382
12,416
373,051
9,009
7,931
457,789

Included within accruals and deferred income is £270,320 (2023 - £325,189) in relation to income deferred on performance-related grants. These grants are considered to contain conditions that require the charity to undertaken certain activities before it becomes fully entitled to the respective grant monies.

Reconciliation of deferred income

At 1 January 2024
Deferred income released
Additional deferred income
At 31 December 2024		 Deferred income
£
325,189
(188,352)
133,483
270,320

6. Funds

General fund
Restricted
fund
E-learning
Events
Journal
Research
Educational
videos
Website
Transfer
between funds		 1 January
2024
£
(438,437)
22,952
-
-
-
295,191
-
-
(120,294)		 Incoming
resources
£
443,027
24,068
7,234
20,273
-
478,026
-
-
972,628		 Transfer
between
funds
£
(265,002)
26,248
59,962
85,793
354
-
-
92,645
-
-		 Outgoing
resources
£
(323,375)
(73,268)
(67,196)
(106,066)
(354)
(248,747)
(92,645)
-
(911,651)		 31 December
2024
£
(583,787)
-
-
-
-
524,470
-
-
(59,317)

The restricted funds are held separately as they relate to specific performance related grant funds and expenditure. They represent various projects for which the donors have specified the use of the funds. These have been grouped into various categories for the purpose of the note above.

Docusign Envelope ID: 86185811-6F3B-4F57-B459-D16FA989843C

The e cancer Global Foundation NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

7. Reconciliation of funds per asset/liability

Fixed assets
Cash at bank and
in hand
Current assets
Current liabilities
Fixed assets
Cash at bank and
in hand
Current assets
Current liabilities		 Unrestricted
funds
£
26,182
173,474
59,367
(48,020)
211,003
Unrestricted
funds
£
35,225
136,053
166,217
(132,600)
204,895		 Restricted
funds
£
-
-
-
(270,320)
(270,320)
Restricted
funds
£
-
-
-
(325,189)
(325,189)		 2024
Total
£
26,182
173,474
59,367
(318,340)
(59,317)
2023
Total
£
35,225
136,053
166,217
(457,789)
(120,294)